Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of post-traumatic stress disorder comprises epidemiological estimates of key patient populations across seven countries worldwide. We report the prevalence of post…

The type 2 diabetes (T2D) therapy market will expand through 2033, supported by polypharmacy and growing use of later-line therapies offering nonglycemic benefits. However, the loss of exclusivity…

Clarivate Epidemiology’s coverage of muscular dystrophy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) plus endocrine therapy are entrenched first-line…

Clarivate Epidemiology’s coverage of binge eating disorder (BED) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Clarivate Epidemiology’s coverage of Waldenstrom macroglobulinemia (WM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

The osteoporosis therapy market is expected to experience rapid growth over the forecast period owing to the increasing prevalence of postmenopausal osteoporosis disease and the increasing uptake…

Clarivate Epidemiology’s coverage of acute respiratory distress syndrome (ARDS) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the…

Clarivate Epidemiology’s coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PsO for each country, as…

Clarivate Epidemiology’s coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PsO for each country, as…

Clarivate Epidemiology’s coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PsO for each country, as…

Clarivate Epidemiology’s coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PsO for each country, as…